-
公开(公告)号：US20180110810A1
公开(公告)日：2018-04-26
申请号：US15837834
申请日：2017-12-11
发明人： Michael J. Sadowsky , Alexander Khoruts , Matthew James Hamilton , Aleh Bobr , Alexa Rachel Weingarden
IPC分类号： A61K35/741 , A61K35/76 , A61K35/74
CPC分类号： A61K35/741 , A61K35/74 , A61K35/76 , Y02A50/473 , Y02A50/475
摘要： The present invention provides freeze-dried compositions that include an extract of human feces and a cryoprotectant, and methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US20200262865A1
公开(公告)日：2020-08-20
申请号：US15998547
申请日：2017-02-15
申请人： Alexander KHORUTS , Michael J. SADOWSKY , Peter DOSA , Kristen STOLTZ , REGENTS OF THE UNIVERSITY OF MINNESOTA
摘要： The present disclosure provides compounds for preventing, treating, and/or reducing the risk of developing a Clostridium-associated disease in a mammalian subject. Also provided are pharmaceutically acceptable salts of such compounds and compositions that include such compounds and/or pharmaceutically acceptable salts thereof.
-
公开(公告)号：US09649343B2
公开(公告)日：2017-05-16
申请号：US15261319
申请日：2016-09-09
IPC分类号： A61K35/38 , A61K35/74 , A61K45/06 , A61K9/19 , A61K35/37 , A61K35/24 , A61K35/741 , A61K9/00 , A61K35/742 , A61K9/16 , A61K47/08 , A61K47/26 , C12N1/20 , A61K35/00
CPC分类号： A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/473 , Y02A50/475 , A61K2300/00
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US10849936B2
公开(公告)日：2020-12-01
申请号：US16313791
申请日：2017-07-03
摘要： The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of a pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.
-
公开(公告)号：US20160375063A1
公开(公告)日：2016-12-29
申请号：US15261319
申请日：2016-09-09
CPC分类号： A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/473 , Y02A50/475 , A61K2300/00
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
6.发明申请FREEZE DRIED FECAL MICROBIOTA FOR USE IN FECAL MICROBIAL TRANSPLANTATION 审中-公开冷冻干燥的FECAL MICROBIOTA用于FECAL微波传输公开(公告)号：US20150374761A1
公开(公告)日：2015-12-31
申请号：US14850318
申请日：2015-09-10
发明人： Michael J. Sadowsky , Alexander Khoruts , Matthew James Hamilton , Aleh Bobr , Alexa Rachel Weingarden
IPC分类号： A61K35/741 , A61K35/37
CPC分类号： A61K35/741 , A61K35/74 , A61K35/76 , Y02A50/473 , Y02A50/475
摘要： The present invention provides freeze-dried compositions that include an extract of human feces and a cryoprotectant, and methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
摘要翻译： 本发明提供了包含人类粪便提取物和冷冻保护剂的冷冻干燥组合物，以及制备和使用这些组合物的方法，包括用于替代或补充或修饰受试者的结肠微生物群的方法，以及用于治疗疾病，病理状况 ，和/或结肠的医源性病症。
-
公开(公告)号：US10286011B2
公开(公告)日：2019-05-14
申请号：US15594087
申请日：2017-05-12
IPC分类号： A61K35/38 , A61K35/74 , A61K45/06 , A61K9/19 , A61K35/37 , A61K35/24 , A61K35/741 , A61K9/00 , A61K35/742 , A61K9/16 , A61K47/08 , A61K47/26 , A61K35/00
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US10028980B2
公开(公告)日：2018-07-24
申请号：US15173134
申请日：2016-06-03
IPC分类号： A61K35/74 , A61K35/742 , A61K9/00 , A61K35/37 , A61K35/24 , A61K35/741 , A61K9/16 , A61K47/08 , A61K47/26 , A61K45/06 , A61K35/00
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
-
公开(公告)号：US20160279176A1
公开(公告)日：2016-09-29
申请号：US15173134
申请日：2016-06-03
IPC分类号： A61K35/74 , A61K9/00 , A61K35/24 , A61K35/742
CPC分类号： A61K35/37 , A61K9/0053 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K35/24 , A61K35/74 , A61K35/741 , A61K35/742 , A61K45/06 , A61K47/08 , A61K47/26 , A61K2035/11 , Y02A50/473 , Y02A50/475 , A61K2300/00
摘要： The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
摘要翻译： 本发明提供了包含人类粪便提取物的组合物和使用这些组合物的方法，包括用于替代或补充或修饰受试者的结肠微生物群的方法，以及用于治疗患者的疾病，病理状况和/或医源性病症的方法 结肠。
-
公开(公告)号：US11819523B2
公开(公告)日：2023-11-21
申请号：US17098243
申请日：2020-11-13
CPC分类号： A61K35/74 , A01N1/02 , A61K9/0053 , A61K9/1623 , A61K9/1682 , A61K9/19 , A61K9/2095 , A61K31/43 , A61P31/04
摘要： The present disclosure provides compositions and methods for treating Clostridium difficile infection (CDI) including primary and recurrent CDI. In particular, the compositions and methods described herein are capable of achieving a CDI clearance rate of at least 80% through a single oral dose of pharmaceutical composition comprising a freeze-dried fecal microbiota preparation.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.025 秒)
